Published in Mol Pharmacol on May 29, 2009
Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol (2012) 2.27
A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ (2010) 2.25
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy. Int J Cell Biol (2010) 1.86
Autophagy as a therapeutic target in cancer. Cancer Biol Ther (2011) 1.84
Autophagy as a therapeutic target in cardiovascular disease. J Mol Cell Cardiol (2011) 1.48
Autophagy as a target for cancer therapy: new developments. Cancer Manag Res (2012) 1.44
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res (2010) 1.43
Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ (2013) 1.42
Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis (2010) 1.23
Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. Ann N Y Acad Sci (2012) 1.21
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. Cancer Biol Ther (2012) 1.12
Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy. Oncogene (2015) 1.11
Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets (2010) 1.11
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res (2010) 1.08
Nexavar/Stivarga and viagra interact to kill tumor cells. J Cell Physiol (2015) 1.06
Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth. Oncogene (2012) 1.04
OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins. Cancer Biol Ther (2010) 1.03
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases. J Cell Physiol (2015) 0.96
Effect of miR-451 on the biological behavior of the esophageal carcinoma cell line EC9706. Dig Dis Sci (2012) 0.92
Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs (2013) 0.92
Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells. World J Gastroenterol (2014) 0.90
RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. Oncotarget (2014) 0.89
Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors. Commun Integr Biol (2012) 0.88
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. J Cell Physiol (2015) 0.87
Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib. World J Hepatol (2014) 0.84
Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J Gastroenterol (2013) 0.84
Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members. PLoS One (2013) 0.83
Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biol Ther (2012) 0.81
Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget (2016) 0.81
Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells. J Cell Physiol (2013) 0.79
Modulation of Autophagy by Sorafenib: Effects on Treatment Response. Front Pharmacol (2016) 0.77
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer. Int J Mol Sci (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Pancreatic cancer biology and genetics. Nat Rev Cancer (2002) 7.36
Essential role for Nix in autophagic maturation of erythroid cells. Nature (2008) 6.49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92
Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. J Biol Chem (2005) 4.56
Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem (2003) 4.55
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res (2009) 4.53
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res (2007) 3.92
BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov (2008) 3.24
MAPK pathways in radiation responses. Oncogene (2003) 3.12
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem (2005) 3.08
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther (2008) 2.96
Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol (2003) 2.63
Histone deacetylases. Curr Opin Pharmacol (2003) 2.58
Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther (2007) 2.56
The CD95 type I/type II model. Semin Immunol (2003) 2.34
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res (2008) 2.17
Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res (2007) 2.15
The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol (2007) 2.07
Loss of macroautophagy promotes or prevents fibroblast apoptosis depending on the death stimulus. J Biol Chem (2007) 2.02
Histone acetylation and chromatin remodeling. Exp Cell Res (2001) 1.85
Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem (2008) 1.84
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) (2005) 1.81
Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Birth Defects Res B Dev Reprod Toxicol (2007) 1.73
Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Mol Cell Biol (2003) 1.72
B-Raf kinase inhibitors for cancer treatment. Curr Opin Investig Drugs (2007) 1.67
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res (2005) 1.62
Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res (2007) 1.59
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res (2008) 1.55
OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol (2008) 1.52
From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology (2007) 1.51
Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther (2008) 1.48
Retracted Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res (2007) 1.39
Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr Opin Cell Biol (2005) 1.37
BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat (2007) 1.33
Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer (2007) 1.33
Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol (2009) 1.25
Bcl-2 family proteins as regulators of oxidative stress. Semin Cancer Biol (2008) 1.23
Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer (2005) 1.22
Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res (2001) 1.22
Sorafenib. Expert Opin Pharmacother (2006) 1.19
Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther (2007) 1.15
Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem (2001) 1.13
Activation of extracellular signal-regulated kinases ERK1 and ERK2 induces Bcl-xL up-regulation via inhibition of caspase activities in erythropoietin signaling. J Cell Physiol (2003) 1.12
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat (2009) 1.12
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther (2008) 1.10
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines. Mol Cancer Ther (2007) 1.03
Kinase inhibitors and cytotoxic drug resistance. Clin Cancer Res (2004) 1.03
The "fuzzy logic" of the death-inducing signaling complex in lymphocytes. J Clin Immunol (2003) 0.96
Targeting cancer and neuropathy with histone deacetylase inhibitors: two birds with one stone? Curr Cancer Drug Targets (2008) 0.82
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med (2011) 4.68
Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology (2008) 4.53
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res (2007) 3.92
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
Congenital glutamine deficiency with glutamine synthetase mutations. N Engl J Med (2005) 3.24
Bile acids as regulatory molecules. J Lipid Res (2009) 3.23
MAPK pathways in radiation responses. Oncogene (2003) 3.12
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem (2005) 3.08
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther (2008) 2.96
Vorinostat. Nat Rev Drug Discov (2007) 2.83
New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res (2010) 2.82
Autophagy in cancer: good, bad, or both? Cancer Res (2006) 2.66
Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther (2007) 2.56
CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun (2006) 2.54
Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol (2011) 2.51
Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res (2003) 2.49
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res (2003) 2.30
Rickettsia felis infection acquired in Europe and documented by polymerase chain reaction. Emerg Infect Dis (2002) 2.26
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res (2004) 2.23
A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood (2008) 2.22
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther (2009) 2.21
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem (2004) 2.18
Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology (2002) 2.16
Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med (2007) 2.14
Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res (2012) 2.14
iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science (2012) 2.14
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res (2010) 2.13
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
An obligatory requirement for the heterotrimeric G protein Gi3 in the antiautophagic action of insulin in the liver. Proc Natl Acad Sci U S A (2007) 2.10
The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol (2007) 2.07
A comprehensive glossary of autophagy-related molecules and processes (2nd edition). Autophagy (2011) 2.02
IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J (2003) 2.00
Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A (2011) 1.98
Integrated metabolic spatial-temporal model for the prediction of ammonia detoxification during liver damage and regeneration. Hepatology (2014) 1.93
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res (2009) 1.92
mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci U S A (2002) 1.91
MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther (2004) 1.90
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther (2009) 1.88
Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy (2012) 1.86
Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology (2002) 1.85
Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res (2007) 1.84
Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun (2008) 1.83
Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res (2007) 1.82
Autophagy and apoptosis: what is the connection? Trends Cell Biol (2011) 1.81
Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci (2002) 1.79
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology (2005) 1.79
Hepatic stellate cells contribute to progenitor cells and liver regeneration. J Clin Invest (2014) 1.77
Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Mol Cell Biol (2003) 1.72
Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur J Cell Biol (2011) 1.71
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res (2012) 1.70
Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther (2010) 1.69
The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology (2007) 1.69
Early clinical experiences with the new influenza A (H1N1/09). Dtsch Arztebl Int (2009) 1.65
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65
Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol (2004) 1.64
mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther (2003) 1.63
The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology (2009) 1.62